Exploring the Hair Loss Risk in Glucagon-Like Peptide-1 Agonists: Emerging Concerns and Clinical Implications

Emerging evidence suggests a potential link between glucagon-like peptide-1 (GLP-1) receptor agonists, specifically semaglutide and tirzepatide, and alopecia, as indicated by a study using FDA data showing elevated reporting odds ratios for hair loss. This association was not observed with the older GLP-1 agonist liraglutide. The mechanisms remain speculative, with possibilities including the influence of GLP-1 agonists on hair growth cycles or telogen effluvium due to rapid weight loss. Clinicians should inform patients about the risk of hair loss, especially those with a history of alopecia, and monitor for signs of telogen effluvium, providing nutritional support as needed. Further research is necessary to confirm these findings and understand the underlying mechanisms.